A new study from the University of Michigan and the University of Kansas could help doctors identify which early-stage breast cancers truly need aggressive treatment. Researchers found genetic markers linked to cancer progression and treatment resistance, which could spare many women from unnecessary mastectomies or chemotherapy. Read the full article to see how a device developed at U-M’s Lurie Nanofabrication Facility and licensed to startup Bloodscan Biotech could transform personalized breast cancer care.
